Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

36.35
-0.5000-1.36%
Post-market: 36.540.1900+0.52%16:42 EDT
Volume:4.01M
Turnover:145.72M
Market Cap:42.35B
PE:60.58
High:36.75
Open:36.37
Low:36.04
Close:36.85
52wk High:38.37
52wk Low:18.21
Shares:1.17B
Float Shares:1.09B
Volume Ratio:0.73
T/O Rate:0.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6000
EPS(LYR):1.21
ROE:9.69%
ROA:5.13%
PB:5.46
PE(LYR):30.04

Loading ...

Stock Track | Teva Pharmaceutical Soars 5.41% in Pre-Market on Strong Q1 Earnings Beat and Emalex Acquisition

Stock Track
·
Apr 29

Teva Pharmaceutical Indus Q1 Adj. EPS $0.53 Beats $0.48 Estimate, Sales $3.982B Beat $3.810B Estimate

Benzinga Earnings
·
Apr 29

Press Release: Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

Dow Jones
·
Apr 29

Teva to acquire Emalex Biosciences for $700M at closing

TIPRANKS
·
Apr 29

Notable companies reporting before tomorrow’s open

TIPRANKS
·
Apr 29

Teva put volume heavy and directionally bearish

TIPRANKS
·
Apr 29

Teva’s Home Ground Schizophrenia Push And What It Could Mean For Investors

Simply Wall St.
·
Apr 28

Teva Pharmaceutical Industries Ltd expected to post earnings of 46 cents a share - Earnings Preview

Reuters
·
Apr 27

Earning Preview: Teva Pharmaceutical this quarter’s revenue is expected to decrease by 4.49%, and institutional views are bullish

Earnings Agent
·
Apr 23

Teva put volume heavy and directionally bearish

TIPRANKS
·
Apr 21

Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After The Home Ground Schizophrenia Platform Launch

Simply Wall St.
·
Apr 19

US appeals court revives Teva lawsuit against Eli Lilly over migraine drug

Reuters
·
Apr 16

Does Biosimilar Wins in Osteoporosis and Allergy Care Change The Bull Case For Teva (TEVA)?

Simply Wall St.
·
Apr 13

Teva Pharmaceuticals Is Maintained at Buy by B of A Securities

Dow Jones
·
Apr 10

Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says

MT Newswires Live
·
Apr 09

BofA Adjusts Price Target on Teva Pharmaceutical Industries to $42 From $38, Maintains Buy Rating

MT Newswires Live
·
Apr 09

How Investors Are Reacting To Teva (TEVA) Advancing Its Biosimilar Pipeline With New FDA and EMA Milestones

Simply Wall St.
·
Apr 04

Teva’s New Biosimilars Test Growth Plan And Earnings Reshaping Potential

Simply Wall St.
·
Mar 31

Teva call volume above normal and directionally bullish

TIPRANKS
·
Mar 31

Barclays Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)

TIPRANKS
·
Mar 30